Point72 Asset Management L.P. lessened its holdings in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 63.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 282,600 shares of the company’s stock after selling 484,400 shares during the period. Point72 Asset Management L.P. owned 0.14% of TherapeuticsMD worth $1,495,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in the company. Principal Financial Group Inc. lifted its stake in TherapeuticsMD by 3.9% during the 2nd quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock valued at $114,000 after acquiring an additional 818 shares during the period. Amalgamated Bank lifted its stake in TherapeuticsMD by 7.2% during the 2nd quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock valued at $104,000 after acquiring an additional 1,322 shares during the period. Legal & General Group Plc increased its position in shares of TherapeuticsMD by 6.5% during the 2nd quarter. Legal & General Group Plc now owns 56,234 shares of the company’s stock valued at $298,000 after purchasing an additional 3,441 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of TherapeuticsMD by 3.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 123,580 shares of the company’s stock valued at $651,000 after purchasing an additional 4,058 shares during the last quarter. Finally, Rhumbline Advisers increased its position in shares of TherapeuticsMD by 3.5% during the 2nd quarter. Rhumbline Advisers now owns 183,408 shares of the company’s stock valued at $967,000 after purchasing an additional 6,232 shares during the last quarter. Hedge funds and other institutional investors own 73.69% of the company’s stock.
TherapeuticsMD, Inc. (TXMD) traded down $0.09 during midday trading on Friday, hitting $6.15. The stock had a trading volume of 1,300,000 shares, compared to its average volume of 2,680,000. The company has a market cap of $1,330.00, a P/E ratio of -15.77 and a beta of 1.06. TherapeuticsMD, Inc. has a 52-week low of $3.50 and a 52-week high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings results on Monday, November 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. The company had revenue of $4.42 million during the quarter, compared to the consensus estimate of $5.36 million. TherapeuticsMD had a negative return on equity of 65.16% and a negative net margin of 457.00%. TherapeuticsMD’s revenue was down 19.7% on a year-over-year basis. During the same period last year, the company earned ($0.13) earnings per share. sell-side analysts predict that TherapeuticsMD, Inc. will post -0.37 earnings per share for the current fiscal year.
In other TherapeuticsMD news, Director Tommy G. Thompson bought 5,000 shares of TherapeuticsMD stock in a transaction on Friday, December 8th. The shares were acquired at an average price of $6.21 per share, for a total transaction of $31,050.00. Following the completion of the purchase, the director now directly owns 3,555 shares in the company, valued at approximately $22,076.55. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 23.92% of the stock is owned by company insiders.
Several research firms have recently commented on TXMD. Zacks Investment Research lowered shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a research report on Friday. Cantor Fitzgerald reissued a “buy” rating and issued a $28.00 target price on shares of TherapeuticsMD in a report on Sunday, January 7th. BidaskClub raised shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 3rd. Noble Financial reissued a “buy” rating on shares of TherapeuticsMD in a report on Friday, December 29th. Finally, Oppenheimer set a $10.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Wednesday, December 20th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $14.50.
ILLEGAL ACTIVITY WARNING: This piece was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/13/therapeuticsmd-inc-txmd-shares-sold-by-point72-asset-management-l-p.html.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.